The Syneos Health Podcast
The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.
Episodes
173 episodes
Asembia AXS25 Series: Reimagining Patient Support: Scaling Access, Affordability and AI Integration with Kelly Carter of Amgen
In this special edition of the Syneos Health Podcast recorded from the floor of Asembia’s AXS25 Summit, host Michael Sarshad sits down with
•
19:12
Asembia AXS25 Series: Redefining Market Access: Patient Support, Technology and Pharma Strategy with Rob Truckenmiller of PharmaCord
In this episode of our Navigating Modern Market Access series, recorded from the floor of Asembia's AXS25 Summit, host Sara Rubin sits down with
•
9:43
Asembia AXS25 Series: Holistic Patient Support with Tiara Green of Accessia Health
In this special episode recorded from the floor at Asembia’s AXS25 Summit, host Michael Sarshad sits down with Tiara...
•
10:10
Asembia AXS25 Series: Modernizing Patient Services: AI, Hybrid Models and Innovation Strategy with Greg Morris of CareMetx
In this special edition of the Syneos Health Podcast recorded from the floor of Asembia’s AXS25 Summit, host Michael Sarshad speaks with
•
28:33
Project Optimus Series: Clinical Pharmacology and Project Optimus
We continue our Project Optimus series with a focus on clinical pharmacology—a foundational element in redefining dose optimization in oncology drug development. Dr. Wael Harb
•
19:09
Asembia AXS25 Series: Navigating Modern Market Access
The biopharma market is booming—but not without turbulence. In this kickoff episode of our special podcast series in collaboration with Asembia, hosts Michael Sarshad, M...
•
13:08
Project Optimus Series: The Role of Biostatistics
As regulatory expectations evolve under the FDA’s Project Optimus oncology dosing initiative, biostatistics is emerging as a central pillar in designing and executing trials that move beyond the traditional maximum tolerated dose (MTD) approach...
•
17:26
Project Optimus Series: Operationalizing Dose Optimization
In this episode of The Syneos Health Podcast, we continue our exploration of Project Optimus and the evolution of dose optimization in oncology drug development. Following our discussion on regulatory expectations in the previous episode, we no...
•
17:55
Opportunities Abound for PDTs, with Click Therapeutics
Unlike general health and wellness apps, Prescription Digital Therapeutics (PDTs) are FDA-authorized, prescribed by healthcare professionals, and rigorously studied in clinical trials. With the global PDT market projected to reach $43 billion b...
•
20:27
Unlocking the Black Box of Psychiatric Clinical Research, with Dr. Rishi Kakar of Segal Trials
In this episode, we welcome Dr. Rishi Kakar, Chief Scientific Officer and Medical Director at Segal Trials. Host Andy Moniz<...
•
17:00
Project Optimus Series: The Regulatory Implications of Project Optimus
In this episode of the Syneos Health Podcast, series host Dr. Wael Harb, Vice President of Medical Management at Syneos Health, continues the exploration of FDA's groundbreaking Project Optimu...
•
18:43
CNS Summit Series: Pioneering Patient Advocacy, with Ryan Brooks from CenExel
For our special series celebrating 15 years of innovation with CNS Summit, host Dr. Alexandria Wise sits down with Ryan Bro...
•
14:39
CNS Summit Series: Future-Proofing Clinical Trials
In this episode, Dr. Alexandria Wise speaks with Steve Rosenberg, CEO of uMotif, recorded from the CNS Summit 2024 e...
•
13:06
CNS Summit Series: Pioneering Psychiatry - Behind the Breakthrough KarXT with Dr. Stephen Brannan
In this inspiring look at the progress and potential in psychiatry research, Dr. Alexandria Wise sits down with Dr. Steph...
•
15:59
CNS Summit Series: Decoding Biology to Radically Change the Lives of Patients, with Dr. Najat Khan of Recursion Pharma
In this episode, host Dr. Alexandria Wise sits down with Dr. Najat Khan, Chief R&D Officer and Chief Commercial Officer a...
•
12:20
CNS Summit Series: Schizophrenia, Clinical Trials and Hope, with Dr. David Walling of Cenexel CNS
In this special edition of The Syneos Health Podcast, host Dr. Alexandria Wise celebrates 15 years of innovation with CNS Summit by interviewing
•
13:44
CNS Summit Series: The Future of Immunology and Personalized Health,with Jane Metcalfe of The Human Immunome Project
Recorded from the 15th annual CNS Summit, Andy Moniz, Vice President of Therapeutic Strategy Innovation at Syneos Health, sits down with
•
13:13
CNS Summit Series: Psychedelics and Beyond, with Kevin Craig of atai Life Sciences
In this episode, Dr. Alexandria Wise celebrates 15 years of innovation at CNS Summit 2024 by sitting down with Kevin Craig<...
•
13:54
CNS Summit Series: Redefining Psychiatry with Science and Compassion, with Dr. David Brown of Community Clinical Research
Join host Andy Moniz, Vice President of Therapeutic Strategy Innovation at Syneos Health, as he sits down with Dr. Davi...
•
10:11
CNS Summit Series: Patient-Centric Innovation at Scale, with Cristina Duran of Evinova
In this episode, recorded from the floor of the CNS Summit, host Andy Moniz, Vice President of Therapeutic Strategy and Innovation at Syneos He...
•
8:35
CNS Summit Series: Celebrating 15 Years of Innovation with Dr. Amir Kalali of CNS Summit
In this special series of the Syneos Health Podcast, we celebrate 15 years of innovation in collaboration with CNS Summit, a community of innovators and life science industry leaders devoted to discovering better, more efficient ways to advance...
•
12:11
Project Optimus Series: Navigating the Realities of Project Optimus
Launched in 2021 by the FDA's Oncology Center of Excellence, Project Optimus seeks to reshape traditional oncology trial designs and dosing paradigms, shifting from maximum tolerated doses to precision dosing strategies. While the FDA's hope wa...
•
20:51
Psychedelics 3.0: Challenges and Opportunities in an Evolving Field
There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to mee...
•
1:02:37